Pharmanutra (BIT:PHN) Third Quarter 2024 Results
Key Financial Results
- Revenue: €28.0m (up 28% from 3Q 2023).
- Net income: €4.27m (up 71% from 3Q 2023).
- Profit margin: 15% (up from 11% in 3Q 2023). The increase in margin was driven by higher revenue.
All figures shown in the chart above are for the trailing 12 month (TTM) period
Pharmanutra Earnings Insights
Looking ahead, revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 4.7% growth forecast for the Personal Products industry in Europe.
Performance of the market in Italy.
The company's shares are up 3.3% from a week ago.
Balance Sheet Analysis
While earnings are important, another area to consider is the balance sheet. We have a graphic representation of Pharmanutra's balance sheet and an in-depth analysis of the company's financial position.
If you're looking to trade Pharmanutra, open an account with the lowest-cost platform trusted by professionals, Interactive Brokers.
With clients in over 200 countries and territories, and access to 160 markets, IBKR lets you trade stocks, options, futures, forex, bonds and funds from a single integrated account.
Enjoy no hidden fees, no account minimums, and FX conversion rates as low as 0.03%, far better than what most brokers offer.
Sponsored ContentNew: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About BIT:PHN
Pharmanutra
A pharmaceutical and nutraceutical company, researches, designs, develops, and markets nutritional supplements and medical devices in Italy, Europe, the Middle East, South America, Far East, and internationally.
Outstanding track record with excellent balance sheet.
Similar Companies
Market Insights
Community Narratives
